Project Grant R21CA292251
Award Date
5/15/25
Completion Date
4/30/27
Dollars Obligated
$402K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Hawaii, USA
Similar Awards
This $447,944 Project Grant was awarded on July 17, 2024 by the National Cancer Institute (CFDA 93.396 Cancer Biology Research) to Baylor College of Medicine in Houston, Texas. The grant supports scientific research aimed at understanding the fundamental biological mechanisms underlying hepatoblastoma (HB), the most common liver tumor in children. The key goals are to: 1) Assess differences in NRF2 activity among primary HB tumors, circulating tumor cells (CTCs), and lung metastases, comparing...
The National Cancer Institute (NCI) awarded a $483,591 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to the University of California, Davis (UC Davis) with an effective date of August 1, 2024 and a planned completion by July 31, 2029. The grant supports research to design, clone, express, and purify novel "bioengineered RNA" (bioRNA) molecules that can target and modulate the metabolism of hepatocellular carcinoma (HCC), the most common form of liver cancer....
This Project Grant award, issued by the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393), aims to improve understanding and treatment of hepatocellular carcinoma (HCC), a prevalent and aggressive form of liver cancer. The $687,679 grant, awarded on December 15, 2024, will fund a multidimensional research plan led by a team at Columbia University's Health Sciences Division. The key objectives of the research are to: 1) computationally...
This is a Project Grant award from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) to the Sanford Burnham Prebys Medical Discovery Institute. The $2,397,277 award, with a performance period from September 2024 to August 2029, supports research to investigate the mechanisms by which metabolic stress and mitochondrial dysfunction contribute to the progression from non-alcoholic steatohepatitis (NASH) to hepatocellular carcinoma (HCC), the most common type of primary...
This $634,061 five-year Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research at the University of Maryland, Baltimore to study the role of tumor-associated plasmacytoid dendritic cells (TAPDC) in the tumor immune microenvironment of liver cancer (hepatocellular carcinoma) in the context of HIV infection. The research aims to define how TAPDC reprogram the tumor microenvironment, modulate anti-tumor T cells, and interact with immune...
This $1,301,250 federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports research by Health Research, Inc. to inhibit myeloid-derived suppressor cell (MDSC) biogenesis and augment the efficacy of immunotherapy for triple-negative breast cancer. The 3-year project, running from March 2025 to February 2028, will explore innovative approaches to enhancing cancer immunotherapy by targeting the mechanisms that...
The National Cancer Institute (NCI) awarded a $441,178 Project Grant under the Cancer Biology Research (CFDA 93.396) program to the Icahn School of Medicine at Mount Sinai. The 5-year grant, awarded on August 6, 2024, supports research focused on understanding the mechanisms driving therapy resistance in pediatric leukemia driven by the NUP98-NSD1 fusion oncoprotein. Key objectives include investigating the developmental dependency of NUP98-NSD1-mediated leukemic transformation, characterizing...
This federal Project Grant award from the National Cancer Institute's Cancer Research Manpower program (CFDA 93.398) provides $127,952 to George Washington University to explore the role of the enzyme HDAC11 in liver cancer and evaluate the potential of HDAC11 inhibitors as a cancer treatment approach. The research aims to understand how HDAC11 promotes hepatocellular carcinoma through its interaction with the splicing factor SF3B2, and to test the effects of HDAC11-specific small molecule...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $563,233 to The Medical University of South Carolina to conduct research aimed at overcoming immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) in the tumor microenvironment. The key objectives are to: 1) determine how the sphingosine kinase 2 (SPHK2)-mediated sphingosine-1-phosphate (S1P) axis induces an immunosuppressive MDSC phenotype, 2) elucidate how SPHK2-S1P...
The National Cancer Institute (NCI) awarded a $145,336 Project Grant under the Cancer Research Manpower (CFDA 93.398) program to the Sloan-Kettering Institute for Cancer Research. The grant, with a period of performance from March 1, 2025 to February 28, 2027, supports research to metabolically reprogram hepatic macrophages to overcome the "immune-desert" tumor microenvironment in hepatocellular carcinoma (HCC). The project aims to determine how macrophages lacking the TSC1 gene can...